Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.
Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.
Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has received the 2021 Europe Technology Innovation Leadership Award in the artificial respiratory market from Frost & Sullivan. This recognition highlights the innovative ART™ system, which aims to reduce the reliance on invasive mechanical ventilation. Frost & Sullivan praised ART for its plug-and-play simplicity and its potential to improve patient care by minimizing lung damage. Despite this progress, the ART system has not yet been approved by the FDA or other regulatory bodies, leaving its market viability uncertain.
Inspira Technologies (Nasdaq: IINN) announced that President & CFO Joe Hayon will present at the Aegis Virtual Event on February 23, 2022, at 8:30am EST. The presentation can be accessed here. Inspira focuses on innovative respiratory technology, developing the ART system to serve as an early extracorporeal support solution, potentially reducing the need for invasive ventilation. The product is still under development and has not received regulatory approval.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) announced the appointment of Daniella Yeheskely-Hayon, PhD, as Chief Technology Officer. She brings extensive experience in biomedical engineering, particularly in blood oxygenation and ECMO devices. Yeheskely-Hayon will lead the research and development of the company’s oxygenators and sensors. Inspira Technologies aims to establish its ART system as a new care standard for acute respiratory patients, although the product has not yet undergone human testing or received regulatory approval.
Inspira Technologies (Nasdaq: IINN) announced an exclusive distribution agreement with Glo-Med Networks for their respiratory support system across six U.S. states, including Texas and Florida. This agreement, with an initial term of seven years, aims to deploy a minimum of 2,121 ART systems and 131,413 disposable units, subject to regulatory approvals. The company projects a potential $174 million market opportunity in Europe, building on previous agreements. Inspira aims to enhance its U.S. market presence and improve respiratory treatment for patients in need.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) has announced that a key component of its ART and ECLS systems is now listed on the FDA Class I 510(k) exempt list. This component aims to mitigate complications from jugular vein cannula movement during patient transport and is expected to enhance safety for awake ECMO patients during mobilization. Although the ART system is designed for cost-effective respiratory support, it has not yet been tested on humans nor received approval from the FDA.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced the appointment of Professor Daniel Brodie to its Scientific Advisory Board. Prof. Brodie, known for his expertise in critical care and extracorporeal life support, leads the Adult ECMO Program at Columbia University/New York-Presbyterian Hospital. His appointment follows other notable additions to the advisory board, enhancing the company's leadership in respiratory support technology. Inspira is developing the ART device, an innovative system aimed at improving oxygenation in respiratory patients, although it has not yet received FDA approval.
Inspira Technologies (Nasdaq: IINN) has signed an exclusive distribution agreement with Innovimed for the ART device in Poland, Czech Republic, and Slovakia. The agreement, with an initial term of 7 years, includes a commitment to purchase a minimum of 1,552 ART devices and 59,040 disposable units. This follows a prior agreement with WAAS Group for potential revenues of $66 million in Spain and Portugal. The ART device aims to reduce the need for invasive mechanical ventilation for respiratory failure patients, pending regulatory approvals.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has filed a Patent Cooperation Treaty application for its ART device, an early-stage extracorporeal respiratory support system. Designed to assist patients while awake, the ART aims to reduce the need for invasive mechanical ventilation. This innovative system enriches blood oxygen levels rapidly, utilizing a low-flow approach that minimizes complications associated with traditional methods. The ART is poised for deployment both in and outside ICU settings, contributing to cost-effective respiratory care.
Inspira Technologies (Nasdaq: IINN) announced the addition of Professor Eddy Fan to its Scientific Advisory Board. Prof. Fan, a critical care specialist from the University of Toronto, aims to enhance the development of Inspira's innovative ART device, designed for respiratory support in patients with acute conditions. This collaboration is expected to improve the clinical applications of the ART device, although it remains untested in humans and lacks regulatory approvals. CEO Dagi Ben-Noon emphasized the significance of Prof. Fan's expertise in advancing hybrid respiratory support solutions.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q3 2021 financial results, showcasing significant progress following an exclusive agreement with WAAS Group for over 1,000 ART systems deployment in Spain and Portugal. The Company raised capital after most IPO warrants were exercised at $5.50 per share. R&D expenses decreased to $1.7 million while net loss increased to $6 million. Notably, Q3 net profit surged to $2.2 million. Cash reserves rose to $17 million, significantly up from $496,000 at year-end 2020, reflecting positive IPO proceeds.
